Bionomics IPO Presentation Deck
Targeting a Large Segment of the Anxiety Market
Acute Anxiety in SAD Represents a Significant Unmet Need
Social Anxiety Disorder (SAD), or Social Phobia, is a
significant and persistent fear of social and
performance-related situations
ii
.
Includes anxiety from everyday social situations as
well as "Fear of Public Speaking"
A disorder that substantially impacts many people's
daily lives
Amongst the largest mental health conditions with lifetime
prevalence affecting >31M Americans
No FDA-approved fast-acting medications for as-needed
treatment
Medications with the right pharmacokinetic profile and a
novel mechanism are needed
-31M
12.1% of adults
at some point
in their lives
-18M
7.1%
prevalence
in adults
Unmet medical need to large patient population
Advancement in care
No FDA-approved fast-acting competition
Ability to potentially achieve large market share
Sources
NIMH Social Anxiety Disorder' dato from 2017 National Comorbidity Survey (NCS) https://www.imh.nih.gow/health/statistics/social-anxiety-disorder.shtml
Anxiety and Depression Association of Americo (ADAA) Social Anxiety Disorder- uinderstand the Facts' https://odas.org/understanding anxiety/social-anniety-disorder
Bionomics Atril
~7M
36% of adults
> 10 years SAD
symptoms
Opportunity
for BNC210
10View entire presentation